Talking Ketamine Podcast

Imagine standing in your bathroom, staring down at your current prescription bottles, terrified that your daily SSRI or SNRI might block the effects of your upcoming ketamine treatment. In Episode 62, we tackle "The Combination Question" by breaking down a highly practical 2026 brief report from Yale by Curran, Hardy, and colleagues. Looking at real-world data from 332 patients with Treatment-Resistant Depression (TRD), researchers uncovered a "beautifully boring" but life-altering reality: there is absolutely no significant difference in ketamine's clinical success regardless of what background antidepressant class a patient is currently taking. We explore the neurobiology behind this phenomenon. Traditional oral antidepressants act like "traffic cops" trying to route signals efficiently on a broken, congested monoamine highway. Ketamine, however, bypasses that system entirely; it acts on the glutamate system to release BDNF, essentially deploying a "construction crew" to pave an entirely new, high-speed neural bypass. Because they operate on completely different biological tracks, they do not interfere with one another. This data offers massive relief. It proves patients do not have to endure agonizing, dangerous drug tapers or risk a severe depressive crash just to clear their system before starting ketamine. Psychiatry is finally moving away from the exhausting merry-go-round of drug "swapping" and entering a much more compassionate era of "layering" treatments. Reference Curran, E., Hardy, M., Katz, R., Rhee, T. G., & Wilkinson, S. T. (2026). Concurrent SSRI, SNRI, or other antidepressant use not associated with differential outcomes in ketamine or esketamine treatment. The Journal of Clinical Psychiatry, 87(2), 25br16294. https://doi.org/10.4088/JCP.25br16294

Imagine knowing exactly what someone is feeling, but your brain forces you to second-guess yourself before you can even react. That is the reality of Treatment-Resistant Depression (TRD), which creates massive "cognitive friction" in social situations. Episode 61 breaks down a fascinating 2026 computational psychiatry study by Yoldas and colleagues that proves severe depression doesn't break your ability to read emotions—it just hits the brakes on your processing speed. Using Hierarchical Drift Diffusion Modeling (HDDM), researchers discovered that TRD patients are perfectly accurate at Facial Emotion Recognition (FER). Their delay is caused by psychomotor slowing and excessively wide "decision boundaries"—meaning their depressed brains require an abnormal amount of evidence before making a choice. The most incredible part? Within just 2 to 4 hours of a single ketamine infusion, patients became significantly faster, normalizing their decision-making speeds. The data shows that ketamine doesn't need to teach the brain to read emotions again; it simply takes the foot off the cognitive brakes. Reference: Yoldas, Z., Cantenys, W., Tronche, M., Hardy, S., Samion, L., Imbault, M., Schmidt, L., & Fossati, P. (2026). Ketamine and facial emotion recognition in treatment-resistant depression: a computational account. OSF Preprints. https://doi.org/10.31234/osf.io/7vb32_v1

In Episode 60, we step outside the realms of mental health and anesthesia to explore a groundbreaking 2026 study by Korkmaz and colleagues that asks a shocking question: can ketamine fight cancer directly? We dive into an in vitro study focusing on HT-29 colorectal cancer cells, exploring the potential of repositioning this common anesthetic in the oncology world. Cancer cells are notoriously hard to kill because they deactivate apoptosis—the body's natural cellular suicide program. This study reveals that ketamine effectively flips this self-destruct switch back on, showing a marked increase in early apoptosis. It alters the delicate balance of key proteins by downregulating Bcl-2, which protects the tumor, and upregulating Bax, which tears the cancer cell apart. At the same time, ketamine acts as an anti-proliferative agent, stopping the cancer cells from aggressively multiplying. How does a dissociative anesthetic achieve this? Molecular docking simulations and gene expression profiling show that ketamine interacts with NMDA and EGFR receptors, disrupting vital signaling pathways like ERK and AKT. While these findings are currently limited to petri dishes rather than human clinical trials, they open the door to a fascinating future where the anesthetics used during tumor-removal surgeries might actively help fight the disease itself.

For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer? We unpack the paradox of using a dissociative anesthetic to sharpen the mind. The secret lies in looking past the acute intoxication phase—the temporary "construction zone"—to the structural remodeling that follows. We explore ketamine's two-phase neuroprotective mechanism: acting first as a "fire extinguisher" to block NMDA receptors and stop toxic glutamate floods (excitotoxicity), and second as "fertilizer" by releasing BDNF to sprout new neural bridges (synaptogenesis). While animal models show a staggering 93.2% success rate in restoring cognitive functions like working memory and spatial learning, the review's single human study on Huntington's disease showed short-term cognitive impairment. We discuss why timing and context are everything: to truly harness this drug, the biological "window of neuroplasticity" must be actively paired with rigorous, targeted neurorehabilitation to guide the brain's rewiring. Reference: Leon-Rojas, J. E., Mascialino, G., Vinueza Mera, L., Hinojosa-Figueroa, M. S., Navas Arias, C. F., Cadena Barberis, E. D., & Sacks-Zimmerman, A. (2026). Ketamine as a potential cognitive enhancer in neurological disorders: Evidence from preclinical and clinical studies. Frontiers in Neurology, 17, 1786249. https://doi.org/10.3389/fneur.2026.1786249

For decades, the clinical focus of treating Major Depressive Disorder has been on alleviating profound sadness. However, traditional monoaminergic antidepressants often fall short of treating anhedonia—the absolute absence of pleasure—and can even cause "emotional blunting" by placing an artificial ceiling on a patient's dopamine-driven joy. In Episode 58, we explore a landmark 2026 systematic review by Faisal and colleagues that synthesizes 13 neuroimaging studies to show how ketamine acts not just as an antidepressant, but as a "pro-joy intervention." We break down the brain's reward architecture into the "Engine" (primitive structures like the striatum and nucleus accumbens) and the "Steering Wheel" (the prefrontal cortex). Chronic depression causes the dendritic spines connecting these regions to wither, leaving the engine dead. But the neuroimaging data is staggering: functional MRI (fMRI) measuring the BOLD signal during the Monetary Incentive Delay task shows that ketamine rapidly reactivates the striatum's response to reward anticipation. We also dive into PET scan data, revealing how ketamine modulates the 5-HT1B serotonin receptor—acting like a "bouncer" to remove the brakes from the dopamine system. Ultimately, this episode offers profound vindication for patients stuck in the gray zone: anhedonia is not a moral failing or a psychological attitude, but a physical deficit in the brain's wiring that ketamine is structurally capable of repairing. Reference: Faisal, H., Le, G. H., Kwan, A. T. H., Wong, S., Cheung, W., Dri, C. E., Cao, B., Rhee, T. G., Bargiota, S., Lo, H. K. Y., Shen, B., Guillen-Burgos, H. F., & McIntyre, R. S. (2026). Effect of ketamine on reward processing in depressive disorders: A systematic review of neuroimaging studies. CNS Spectrums. https://doi.org/10.1017/S109285292610087X

In Episode 57, we explore a groundbreaking 2026 study out of Hungary by Koncz and colleagues that challenges the foundation of modern psychiatry: do you actually have to "trip" to heal? For years, the pharmaceutical industry has searched for a sanitized, at-home version of ketamine, hoping that R-ketamine (arketamine) could deliver neuroplasticity without the intense psychotomimetic effects of standard S-ketamine (esketamine). By utilizing quantitative EEG (qEEG) signals, researchers discovered the "Gamma-Delta Shift"—the electrical signature of the brain actively rewiring. S-ketamine acts like a controlled forest fire: it triggers a massive, high-frequency "gamma storm" (the trip) which creates a massive cellular energy debt. This debt forces a mandatory "delta rebound" during deep sleep, which is when the actual physical remodeling and synaptic plasticity occur. The shocking twist? Even at four times the normal dose, arketamine completely failed to trigger this shift. This perfectly mirrors its recent failure in human clinical trials, where it did not show a statistically significant antidepressant effect compared to a placebo. The data draws a clear line: you cannot bypass the chaotic exertion phase and still get the structural repair. The altered state isn't a side effect to be engineered away; it is a necessary feature of the cure. Reference: Koncz, S., Pothorszki, D., Papp, N., Pál, D., & Bagdy, G. (2026). Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon. British Journal of Pharmacology, 1-15. https://doi.org/10.1111/bph.70399

In Episode 56, we explore a fascinating 2026 pharmacokinetics study by Otto and colleagues that completely changes how we view oral ketamine for Treatment-Resistant Depression (TRD). When taken orally, ketamine hits a massive biological roadblock: the liver's "first-pass effect". The liver acts as an aggressive tollbooth, metabolizing almost all of the parent drug and transforming it into a high volume of a metabolite called (S)-norketamine before it reaches the wider bloodstream. Using advanced Pharmacokinetic-Pharmacodynamic (PKPD) modeling, researchers discovered a mind-bending reality. While intravenous ketamine drips rely on the original parent drug to drive the therapeutic high, the subjective experience of an oral pill is almost entirely driven by its metabolite, (S)-norketamine. Because this metabolite is a "clunkier key" with a lower affinity for NMDA receptors, it requires a massive volume to overwhelm the system and produce the necessary psychotomimetic effects. The study's simulations reveal a major clinical hurdle: standard oral doses (like 0.2 or 0.45 mg/kg) fall significantly short of matching the proven therapeutic experience of an IV drip. To achieve those same effects, oral doses must be drastically increased to approximately 1.0 mg/kg. We discuss what this means for the future of TRD treatment, the need for new safety monitoring strategies due to delayed absorption, and the unsettling realization that the pills we swallow aren't always the chemicals that heal us. Reference: Otto, M. E., Jacobs, G. E., van Mechelen, J. C., Borghans, L. G. J. M., van Hasselt, J. G. C., & Aulin, L. B. S. (2026). Pharmacokinetics and pharmacodynamics of intravenous and oral (S)-ketamine: Investigating metabolite contribution to subjective effects. British Journal of Clinical Pharmacology, 1-12. https://doi.org/10.1002/bcp.70503

Bipolar depression creates an agonizing clinical trap: patients are paralyzed by severe lows, yet traditional antidepressants take weeks to work and carry the terrifying risk of an "affective switch"—triggering a manic episode or rapid cycling. In Episode 55, we explore a 2026 review by Queissner and colleagues showing how ketamine and esketamine rewrite the rules by bypassing serotonin and targeting the brain's glutamate "gas pedal". We unpack the staggering data: an odds ratio of 10.68 for rapid relief, with the REAL-ESK study showing zero cases of manic switching in real-world patients using intranasal esketamine. The episode dives deep into the biology, exploring Rizzo's 2025 discovery of ketamine's dual mechanism (NMDA and mu-opioid receptor modulation) that specifically targets anhedonia by restoring dopamine to the brain's reward center. Finally, we discuss why ketamine isn't a solo act—and how foundational mood stabilizers like lithium act as a safety net that synergizes with ketamine to spark central neuroplasticity and structural brain repair. Reference: Queissner, R., Fellendorf, F., & Reininghaus, E. Z. (2026). Ketamine as an NMDA-modulating therapy in bipolar disorder: Rationale and evidence. Frontiers in Psychiatry, 17, 1777402. https://doi.org/10.3389/fpsyt.2026.1777402

For decades, medicine has sold us the comforting "light switch" theory: under general anesthesia, we simply cease to exist for a few hours. But in Episode 54, we unpack Bruno Tonetto’s terrifying and fascinating 2026 paper, "Conscious Under Anesthesia," which argues that we have confused the silence of the body with the absence of the mind. We explore the "broken speaker" analogy, revealing how paralytics trap patients in a silent body, while premedications like Midazolam act as chemical memory wipers (anterograde amnesia) to ensure the experience is forgotten. The most chilling evidence? The Isolated Forearm Technique, where researchers block the paralytic from reaching one arm, revealing that up to a third of paralyzed, "unconscious" patients can squeeze a hand to answer complex questions—yet remember absolutely nothing upon waking. Finally, we tackle the "Ketamine Paradox." As an approved anesthetic that triggers hyper-vivid, mystical experiences, ketamine completely breaks the traditional "production model" of the brain. Instead, Tonetto argues for the "constraint model," suggesting the brain is not a turbine generating consciousness, but a "reducing valve" filtering it. When ketamine unplugs the sensory inputs, the filter breaks, and the mind expands. Reference: Tonetto, B. (2026). Conscious under anesthesia: What the clinical evidence actually shows. Project: Return to Consciousness. https://brunoton.github.io/return-to-consciousness/rtc/ and https://brunoton.github.io/return-to-consciousness/exports/pdf/cua.pdf

In episode 53, we move out of the sterile lab and into the messy real world, examining a large naturalistic study of 224 patients from an Austin clinic. The paper by Kosted and colleagues compares standard "infusion-only" ketamine treatment against Ketamine-Assisted Therapy (KAT) to answer a costly question: is paying for a therapist to be in the room actually worth it? The average results were shocking: across the entire sample, the therapy group didn't fare any better than the infusion-only group. But when researchers sliced the data by age and Adverse Childhood Experiences (ACEs), a much more complex story emerged. We unpack the counterintuitive "super responder" effect, where patients with high childhood trauma saw the most dramatic biological healing. For young adults under 30, the medicine alone was often more effective, suggesting that talk therapy might actually interrupt the "bake" of neuroplasticity by shifting activity to the analytical brain too soon. Conversely, for patients over 50, therapy was essential; without a human connection to help navigate and rewire decades of compensatory behaviors, the ketamine alone often fell short. Finally, we discuss the practical implications of the "decelerating curve" of improvement—where the most dramatic drops in depression occur early in treatment—and why the future of personalized psychiatry must look beyond DNA to a patient's lived biography. Reference: Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026). Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample. Journal of Affective Disorders, 402, 121350. https://doi.org/10.1016/j.jad.2026.121350

For the podcast's one-year anniversary, we zoom out from single studies to examine a comprehensive masterpiece: the doctoral thesis of Jolien K.E. Veraart, representing nine years of research (2016–2026) at the University of Groningen. This document moves beyond the initial hype of "does it work?" to the mature, difficult questions of long-term maintenance and safety. We unpack the critical concept of auto-induction—the discovery that the liver eventually "learns" to metabolize ketamine so efficiently that stable doses stop working, creating a bioavailability trap that looks like relapse but is actually just enzymatic efficiency. The episode also tackles the "nightmare" of oral dosing, where absorption is so variable that it makes consistent treatment a roll of the dice. Finally, we discuss the philosophical shift in Veraart’s work: moving away from the "trip" as the cure and toward a model where ketamine simply "softens the clay" of the brain. This places the responsibility back on set and setting not just as a safety measure, but as the tool that sculpts the neuroplastic brain into a healthier shape. Reference: Veraart, J. K. E. (2026). Ketamine for depression: Moving from research to clinical practice [Doctoral thesis, University of Groningen]. https://doi.org/10.33612/diss.1484805904

In the world of ketamine therapy, there is a distinct divide: the FDA-approved, insurance-covered "Gold Standard" (Esketamine/Spravato) versus the cheap, off-label generic (Racemic Ketamine). In this episode, we step into the ring to judge "The Nasal Spray Wars" using a groundbreaking 2026 meta-analysis by Bahji and colleagues published in the Journal of Affective Disorders. We break down the "skim milk vs. whole milk" pharmacology: Esketamine isolates just the S-isomer, while generic ketamine contains both the S and R isomers. Big Pharma argues the isolate is cleaner, but the data tells a different story. We reveal the study's stunning conclusion: there is no significant difference in symptom relief between the two. In fact, the "cheap" generic showed higher remission rates and lower dropout rates than its expensive counterpart. The discussion tackles the massive elephant in the room: accessibility. With Spravato costing thousands of dollars per month and requiring strict in-clinic monitoring, we ask if the "premium" price tag is buying better health or just a patent. We conclude with a verdict for patients paying out-of-pocket: choosing the generic isn't "settling"—it may actually be the more effective, and certainly the more sustainable, path to recovery. Reference: Sarlon, J., Thomi, D., Brühl, A. B., Liwinski, T., & Lang, U. E. (2026). Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study. Journal of Affective Disorders, 400, 121208. https://doi.org/10.1016/j.jad.2024.07.054

For decades, we’ve imagined the synapse as a "chemical soup"—a messy place where one neuron sprays neurotransmitters at another, hoping for a connection. But in this milestone 50th episode, we use the lens of the groundbreaking book Nano-Organization of the Synapse to reveal the stunning reality: the synapse is actually a piece of high-precision Swiss watchmaking. We explore the revolution in super-resolution microscopy (like STORM and cryo-electron tomography) that has allowed us to see the nanocolumn—a dedicated architectural alignment where a presynaptic "launch pad" (controlled by the protein Munc13) sits perfectly opposite a postsynaptic "receiver slot" (held by PSD95). This "trans-synaptic alignment" ensures that every signal is a sniper shot, not a sprinkler spray. The episode dives into the three modes of transmission—synchronous (the fast lane), asynchronous (the stutter), and the critical spontaneous release (the "ghost in the machine"). We discuss the theory that depression is a failure of this nanoscopic geometry, where the "ghost" signal reinforces a broken state. Finally, we explain how ketamine acts as a rapid repair crew: by silencing the spontaneous noise at NMDA receptors, it triggers a panic-like "homeostatic plasticity" that forces the neuron to realign its columns, add more AMPA receptors (volume knobs), and restore the "liquid crystal" dance of the synapse. Reference: Kavalali, E. T. (Ed.). (2026). Nano-organization of the synapse: From structure to function (Vol. 48). Springer Nature Switzerland. https://doi.org/10.1007/978-3-032-12594-1

For decades, the "Monoamine Dogma" ruled psychiatry: the brain was a chemical soup, depression was a lack of serotonin, and the cure was simply "filling the tank." But there was always a glitch in the matrix—why did it take weeks for pills to work if the chemistry changed in hours? In this special 25th-anniversary episode, we review a retrospective paper from 2026 that traces the history of the "Neuroplastic Revolution." We go back to the turning point: the accidental discovery that ketamine could stop depression in four hours, proving the problem wasn't a lack of fuel, but broken wiring. We unpack the science of structural repair: how ketamine blocks the "disappointment center" (the lateral habenula), wakes up the "construction foreman" (mTOR), and releases BDNF (Miracle-Gro for the brain) to physically regrow lost connections. We also look at the macro level, exploring how this "reboot" disrupts the Default Mode Network to stop the loop of rumination. Finally, we discuss where we are today in 2026: the age of Precision Psychiatry, where we stop guessing and start treating the specific biological cause—whether it’s inflammation, glutamate, or connectivity. Reference: Bulek, D., & BaDour, S. (2026). From monoamine deficits to multiscale plasticity: Twenty-five years of ketamine and the neurophysiology of depression. Journal of Neurophysiology. https://doi.org/10.1152/jn.00516.2025

Patients with diabetes often face a brutal "syndemic"—a tangled web of chronic illness, Relentless nerve pain (neuropathy), and severe depression, all fueled by a common biological enemy: metabolic inflammation and Advanced Glycation End-products (AGEs). In this episode, we explore why ketamine, with its rapid antidepressant and non-opioid painkilling properties, looks like the perfect "two birds, one stone" solution on paper. But in practice, it requires walking a high-stakes "metabolic tightrope." We dive into the complex risks: The Glucose Rollercoaster: Ketamine can trigger a stress response that spikes blood sugar (hyperglycemia), yet in Type 1 diabetics, it has also been linked to dangerous, delayed drops (hypoglycemia). The Liver "Traffic Jam": In Type 2 diabetes, fatty liver disease can clog the body's filter, slowing down drug clearance and potentially turning a normal dose toxic. The Metformin Paradox: We discuss preclinical warnings that metformin—the most common diabetes drug—might actually blunt ketamine’s antidepressant effects. The solution? A move away from "one-size-fits-all" medicine toward Model-Informed Precision Dosing—using a patient’s kidney function, liver health, and genetics to calculate the perfect, safe dose. Reference: Sukhram, S. D., Sanchez, M., Anidugbe, A., Kupa, B., Edwards, V. P., Zia, M., & Yilmaz, G. (2026). Ketamine in diabetes care: Metabolic insights and clinical applications. Pharmaceutics, 18(1), 81. https://doi.org/10.3390/pharmaceutics18010081

Clinicians measure success in symptom scores and receptor occupancy, but for patients with Treatment-Resistant Depression (TRD), success is defined by something far more personal: the return of connection, clarity, and "life." In this episode, we amplify the "Patient's Voice" through a comprehensive synthesis of qualitative studies by Walasek and colleagues. We trace the emotional arc of treatment, starting with the profound ambivalence of patients who see ketamine as a "last resort"—terrified it will be just another failure in a long line of disappointments. We then step inside the acute experience itself, often described as a "rollercoaster" where euphoria and panic can flip on a dime, making the safety of the setting and the empathy of the staff critical to preventing trauma. The discussion challenges the medical model's obsession with dissociation as a measurable "active ingredient," revealing that patients value the meaning they make of the experience—the moments of insight and emotional release—far more than the intensity of the "trip" itself. Finally, we expose the hidden barriers to care: the crushing financial burden, the stigma of using a "party drug," and the finding that patients often attribute up to 50% of their therapeutic outcome not to the molecule, but to the kindness and support of the clinical staff.

For decades, the "trip" caused by ketamine—sensory detachment, time warping, and out-of-body experiences—was seen as a nuisance, a "bug" to be tolerated during anesthesia. But a groundbreaking 2025 review paper by Berra and colleagues asks a provocative question: What if dissociation is actually the point? In this episode, we dive into the "Science of Dissociation," exploring the spectrum from simple "checking out" (daydreaming) to profound depersonalization and derealization. We analyze the "switch" in the brain—how ketamine blocks NMDA receptors on inhibitory interneurons, unleashing a glutamate burst that disrupts the Default Mode Network (DMN). This disruption forces the brain into a "chaotic" state of higher entropy, breaking rigid, depressive thought loops and allowing the mind to form new, healthier connections. We also look to the future of "non-hallucinogenic" alternatives like hydroxynorketamine (HNK), which promote neuroplasticity without the trip. This raises a fundamental philosophical and clinical question: Is the conscious experience of an altered state the "price of admission" for healing, or can we bypass the mind to fix the brain? Reference: Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025). Cortical mechanisms contributing to ketamine-induced dissociation. The Neuroscientist, 1–17. https://doi.org/10.1177/10738584251403946

For decades, ketamine has been viewed primarily through two lenses: a safe anesthetic or a rapid-acting antidepressant "reset button." But a new paper by Sophie Holland argues we may be missing half the picture. This episode challenges the binary view of ketamine by exploring two distinct therapeutic pathways defined essentially by dose: the Psychedelic and the Psycholytic. The Psychedelic Path (High Dose): We examine the "reset button" model—intense, dissociative experiences driven by a massive glutamatergic burst. The goal here is ego dissolution, allowing patients with severe, treatment-resistant depression or PTSD to emotionally decouple from trauma and achieve rapid symptom reduction. The Psycholytic Path (Low Dose): We contrast this with the "relational tool" model. Here, the goal isn't to leave the body, but to loosen the ego just enough to lower psychological defenses. This trance-like state allows patients to stay connected to their therapist, accessing repressed memories and processing emotions in real-time with less fear. The discussion also tackles the debate over ketamine’s classification—is it truly a psychedelic? While chemically distinct from "classic" psychedelics like psilocybin, its ability to induce neuroplasticity (acting as a psychoplastogen) and non-ordinary states of consciousness places it firmly in the psychedelic therapeutic spectrum. Finally, we look at the physical realities. With chronic high-dose use linked to ulcerative cystitis, does the low-dose psycholytic approach offer a safer, more sustainable model for long-term relational work?. We also touch on the frontier of "betterment of the well," exploring how low-dose protocols might enhance creativity, teamwork, and problem-solving in healthy individuals. Reference: Holland, S. (2025). Ketamine reimagined: Distinguishing psychedelic and psycholytic modalities for next-generation therapies. Silva Wellness. DOI: 10.22541/au.176538434.48451693/v1

Sickle Cell Disease (SCD) pain crises are the leading cause of hospitalization for affected children, causing excruciating vaso-occlusive episodes where misshapen blood cells block oxygen flow to tissues. For decades, the standard treatment has been high-dose opioids, but this often leads to tolerance, inadequate relief, and the dangerous paradox of opioid-induced hyperalgesia—where the treatment actually makes the nervous system more sensitive to pain. In this episode, we analyze a massive cross-sectional study from 44 U.S. children’s hospitals involving over 74,000 admissions. The study asks a critical question: Can ketamine, an NMDA receptor antagonist that "turns down the volume" on central sensitization, break the cycle of pain where opioids fail? The findings reveal a slow but steady rise in ketamine use (doubling from 2.3% in 2016 to 5.7% in 2023), mostly reserved for older children with severe disease markers like chronic pain or hydroxyurea use. But the most stunning insight is about timing. The study found that when ketamine was administered early (within the first 3 days of admission), it cut the median hospital Length of Stay (LOS) in half—from 12 days to just 6 days—and drastically reduced the days patients needed IV opioids. Despite these compelling results, huge gaps in care remain, with some hospitals using ketamine in 20% of cases and others in 0%. We discuss the institutional barriers, stigma, and red tape that prevent clinicians from using this powerful tool when it matters most: early in the crisis. Reference: Jenkins, A. M., Hendry, E., Power-Hays, A., Valentino, M., Hall, M., Kyler, K. E., Antoon, J. W., Tang Girdwood, S., Goldman, J. L., Morel, A. N., Savage, T. J., Orth, L. E., & Archer, N. M. (2025). Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016826

"Will this actually work for me?" It is the most critical question patients ask before investing time, money, and hope into ketamine therapy. In this episode, we analyze a massive body of research—including a systematic review of 112 studies and a real-world analysis of 77 patients —to find actionable predictors of success. The results are reassuringly broad: factors like age, sex, depression severity, trauma history, and even the intensity of dissociation do not predict whether ketamine will work. However, the data reveals two powerful signals that every patient should know: The "Line in the Sand": The strongest negative predictor is pharmacological resistance. Patients who have failed more than six previous antidepressant trials were significantly less likely to respond to ketamine. The "Perfect" Positive Signal: Researchers identified an early marker of success after just the second infusion. A tiny symptom reduction of just 4.1% on the PHQ-9 scale carried a Positive Predictive Value of 1.0—meaning 100% of patients who hit this mark went on to achieve a clinical response. Crucially, we explain why early non-improvement does not mean failure, as nearly half of patients who showed zero improvement after dose two still achieved a response by the end of treatment. Join us to learn why ketamine might need to be considered earlier in the treatment timeline, before pharmacological resistance sets in. Reference: Syed, O. A. (2025). Predictors of the antidepressant effects of ketamine and psychedelic substances [Master's thesis, University of Toronto]. TSpace Repository.

Surgery is a trauma that wrecks sleep, and for vulnerable patients, Post-Operative Sleep Disturbance (PSD) is a serious complication linked to delirium, increased pain, and slowed recovery. In this episode, we dive into a fascinating study that connects three seemingly unrelated dots: ketamine, sleep, and the oral microbiome. Researchers treated 130 high-risk surgical patients with a continuous low-dose infusion of esketamine. The clinical results were striking: the rate of PSD dropped from 65% in the control group to just 43% in the esketamine group. Patients reported significantly better sleep quality and required far fewer opioids like hydromorphone. But the real surprise was found in their saliva. The study revealed that esketamine treatment actively reshaped the oral microbial community—boosting beneficial bacteria like Streptococcus while suppressing groups like Bacteroidota that were linked to poor sleep. Why would an IV anesthetic change mouth bacteria? We explore the leading theories: Systemic Anti-Inflammation: Surgery floods the body with pro-inflammatory cytokines (a "systemic fire"). Ketamine’s powerful anti-inflammatory properties may calm this environment, making the host less hospitable to stress-related microbes. The Gut-Oral Axis: Ketamine may influence the gut microbiome, with effects rippling up to the mouth to stabilize the body's entire ecosystem. This research challenges us to rethink how psychiatric drugs work—not just by hitting receptors in the brain, but by restoring ecological balance to the nerves, immune system, and the trillions of microbes that live within us. Reference: Li, X.-Y., Qiu, D., Du, N., Hashimoto, K., Wang, X.-M., & Yang, J.-J. (2025). Esketamine prevents postoperative sleep disturbance in patients with preoperative sleep disorders: A role for oral microbiota. Translational Psychiatry, 15(1), 501. https://doi.org/10.1038/s41398-025-03705-9

Catatonia is often misunderstood as simple immobility, but it is a terrifying, life-threatening syndrome of stupor, mutism, and extreme negativism—a state where the brain is essentially "frozen." For decades, the standard protocol has been to step on the "brake pedal" using GABA-ergic drugs like lorazepam, followed by Electroconvulsive Therapy (ECT) if medication fails. But what happens when the brakes don't work, and ECT is medically unsafe or unavailable? This episode analyzes a new systematic review of 10 unique case reports that suggests NMDA receptor antagonists like ketamine and esketamine could be the "skeleton key" for these desperate scenarios. We explore the neurochemistry of switching from the failed inhibitory (GABA) pathway to directly targeting the excitatory (Glutamate) system. The theory? Refractory catatonia may be driven by a massive glutamate hypo-function—the brain's engine isn't firing—and ketamine triggers the necessary surge to reset the circuit. The clinical results discussed are striking: 100% of the patients in the review showed symptom improvement, often within hours to days. We also debunk the common fear that ketamine might destabilize these fragile patients by triggering mania or psychosis; the review found these risks were not supported by the data. Finally, we highlight the practical game-changer of intranasal esketamine, which allows clinicians to bypass the resistance often seen in mute, withdrawn patients who cannot swallow pills. Reference: van der Meer, P. B., Verboeket, S., Slooter, A. J. C., Schoones, J. W., van Noorden, M. S., Somers, M., Batalla, A., & Dols, A. (2025). Treatment with (es)ketamine in catatonia: A systematic review of case reports. The Journal of Clinical Psychiatry, 86(4), Article 25br15940. https://doi.org/10.4088/JCP.25br15940

We move beyond depression and anesthesia to examine ketamine's role in fighting one of the most severe types of chronic pain imaginable: Complex Regional Pain Syndrome (CRPS). This condition is marked by wildly disproportionate and persistent pain , exemplified by the case of a 15-year-old athlete whose simple hand fracture healed, but whose nervous system got stuck in a pathological pain loop. The core problem in CRPS is central sensitization—the brain and spinal cord jamming the "volume knob" for pain on maximum, where a light touch (allodynia) is interpreted as excruciating. Traditional treatments fail because the problem is upstream, residing in the central nervous system (CNS). Specialists employed a clever, multimodal strategy to finally break this refractory pain cycle: Gabapentin: To calm general static in the nervous system. Continuous Nerve Block: A regional anesthetic to temporarily silence all incoming peripheral pain signals from the arm. Continuous Ketamine Infusion: The NMDA receptor antagonist was the core component, performing a "software reboot" on the CNS. Ketamine acts as a master switch, physically blocking the NMDA receptor that powers the central sensitization system, thereby interrupting the vicious wind-up cycle. The results were dramatic: pain, which was agonizing, dropped from 7/10 to 2/10 within 24 hours, resolving completely in 48 hours. Allodynia resolved, enabling the essential physiotherapy needed for long-term recovery. This case report is a powerful demonstration of ketamine's versatility, showing it can act not just as a painkiller, but as a system reset for neurological conditions rooted in faulty learning. Reference: Medikondu, H., Davit, A., & Visoiu, M. (2025). Effective Adolescent Hand CRPS Type 1 Treatment Using Ketamine, Gabapentin, and Supraclavicular Nerve Block Catheter. Preprints.org. https://doi.org/10.20944/preprints202511.0755.v1

Chronic mental illnesses like severe MDD (major depressive disorder) and PTSD are alarms, not just for the mind, but for the body. This episode explores the fact that ongoing trauma and depression accelerate biological aging, leading to reduced health span and higher risks for chronic diseases. But can rapid, effective psychiatric treatment actually reverse this damage? We dive into a compelling pilot study that gave a series of six sub-anesthetic ketamine infusions to 20 participants with treatment-resistant depression or PTSD. The researchers used second-generation epigenetic clocks to measure biological age—the actual cellular wear and tear, separate from chronological age. The most advanced clock used, OMICs-AGE, integrates DNA methylation with surrogates for over 40 proteins, metabolites, and clinical markers across eight physiological systems, showing the strongest link to mortality risk. The findings are potentially groundbreaking: Age Reversal: The study found a clear, statistically significant reduction in epigenetic age across several markers after treatment. Critically, the signal captured by OMICs-AGE held up under stringent statistical correction, suggesting a genuine biological age deceleration. The Mechanism: This reversal is linked to specific anti-aging pathways. Ketamine treatment led to a significant reduction in CD4 T memory cells, which are markers for systemic inflammation and aging (immunosenescence). Further analysis revealed shifts in metabolic and neuroimmune markers clustered around circadian sleep regulation and T-cell differentiation. While this was a small pilot study without a non-treatment control group , the robustness of the OMICs-AGE signal suggests a profound implication: the ultimate longevity treatment may lie not in anti-aging creams, but in aggressively treating the mental illness that accelerates the biological clock in the first place. Mental health truly is longevity health. Reference: Dawson, K. L., Carangan, A. M. J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Mendez, T. L., Smith, R. M., Dawson, M. S., Mallin, M. P., Higgins-Chen, A. T., & Dwaraka, V. B. (2025). Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study. Translational Psychiatry, 15(1), 452. https://doi.org/10.1038/s41398-025-03683-y

The KARMA-Dep2 trial delivered a shocking headline: up to eight serial ketamine infusions were no better than the midazolam placebo for hospitalized adults with moderate to severe depression. In an era of intense hope for ketamine's rapid antidepressant effects, this result demands a closer look. This episode critically dissects why this large, pragmatic trial may have failed to show a significant difference, focusing on a central challenge in ketamine research: blinding. The Active Placebo Problem: The trial used midazolam as an active placebo to mimic the transient side effects (like sedation and disorientation) of ketamine. However, previous meta-analyses (Wilkinson et al., 2019) show that midazolam itself produces a substantial placebo/expectancy effect (around an 18% response rate), effectively setting a high floor that makes the pharmacological benefit of ketamine harder to detect. The Unblinding Issue: We contrast the KARMA-Dep2 outcome with the Dwyer et al. (2021) adolescent trial, where ketamine was significantly better than midazolam. Crucially, the adolescent study revealed a massive confound: 10 out of 10 patients on ketamine correctly guessed their treatment, illustrating the "functional unblinding" that allows expectation to heavily influence results. The Measurement Challenge: We discuss the inherent difficulty of using scales designed for slow-acting drugs (like MADRS and HAMD) to measure ketamine's rapid antidepressant effects, leading to measurement workarounds like carrying over scores for symptoms like sleep and appetite. The core question remains: Does midazolam give a truly realistic estimate of ketamine's effect, or does chasing the "perfect blind" with an active placebo simply obscure the real-world value of a drug whose unique, powerful experience is inseparable from its clinical benefit? Resources: Wilkinson, S. T., Farmer, C., Ballard, E. D., Mathew, S. J., Grunebaum, M. F., Murrough, J. W., Sos, P., Wang, G., Gueorguieva, R., & Zarate, C. A., Jr. (2019). Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology, 44, 1233–1238. https://doi.org/10.1038/s41386-019-0317-8 Dwyer, J. B., Landeros-Weisenberger, A., Johnson, J. A., Londono Tobon, A., Flores, J. M., Nasir, M., Couloures, K., Sanacora, G., & Bloch, M. H. (2021). Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal of Psychiatry, 178(4), 352–362. https://doi.org/10.1176/appi.ajp.2020.20010018 Jelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Whooley, E., McDonagh, K., McDonogh, S., Loughran, O., Shackleton, E., Igoe, A., Thompson, S., Mohamed, E., Nguyen, D., O'Neill, C., Walsh, C., & McLoughlin, D. M. (2025). Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2025.3019 

For years, the most recognized physical risk of chronic ketamine abuse has been bladder damage, but a new clinical puzzle is emerging: severe injury to the liver and bile ducts, known as Ketamine-induced Sclerosing Cholangitis (K-SC). This episode dives into a recent case series detailing patients—including older and female European users—broadening the picture of who is at risk. Sclerosing cholangitis is a progressive condition where chronic inflammation leads to severe scarring and narrowing of the bile ducts. This obstruction causes bile backup (cholestasis), which, if unchecked, can result in irreversible cirrhosis—often making a liver transplant the only option. We explain why laboratory markers like GGT and ALP are critical red flags for this damage. How does this anesthetic target the liver’s plumbing? The leading hypothesis suggests chronic, high-dose exposure over time causes sustained spasms due to ketamine’s effect on NMDA receptors located in the bile duct smooth muscle. Crucially, the severity of this liver damage often tracks directly with the severity of a patient’s urinary symptoms, suggesting a systemic toxic effect on similar smooth muscle tissues in both the bladder and the biliary system. Using diagnostic criteria, physicians confirmed K-SC by ruling out other look-alike conditions (like PSC, which is tied to IBD). The strongest evidence linking the drug to the severe damage was the dramatic clinical improvement in lab results immediately after patients ceased ketamine use. The main takeaway for anyone concerned is non-negotiable: the absolute first line of defense is immediate and permanent cessation of all ketamine use. Management requires a comprehensive multidisciplinary team—gastroenterologists, urologists, and addiction specialists—to manage the devastating progression and provide essential addiction support. This exploration underscores a tragic potential consequence of long-term abuse and the urgent need for more longitudinal research. Source Research Paper: Vanrusselt, A., Nijs, J., Van den Bergh, L., Schoofs, N., Smets, S., Strybol, D., & Rappaport, A. (2025). Ketamine-induced sclerosing cholangitis: a case series. Acta Gastro-Enterologica Belgica, 88(3), 271–276. https://doi.org/10.51821/88.3.13914 The post Ketamine and Liver Damage? appeared first on Talking Ketamine Podcast.

This episode breaks down a truly radical theory of consciousness: The General Resonance Theory (GRT). Forget the traditional idea that consciousness comes from synapses firing—GRT proposes that it emerges from near-instantaneous, resonant electromagnetic field interactions within the brain, moving information up to 40,000 times faster than slow neuronal spikes. This electrical “field” is the true substrate of our unified sense of reality. We use this theory to answer the biggest question in psychedelic science: Why does ketamine cause dissociation? While classic psychedelics are seen as “field resonance enhancers” that create feelings of unity and global synchronization, ketamine does the precise opposite. We reveal the precise mechanism: ketamine preferentially removes the “brakes” (NMDA receptors on inhibitory GABA neurons). This results in fragmented hyperactivity. Local circuits go wild, but they lose the coherence needed for a unified sense of self, leading to the subjective experience of dissociation and the ultimate breakdown of integrated consciousness—the K-hole. Electrically, this shows up as a measurable decoupling between the frontal and parietal regions, the key areas for self and spatial awareness. Finally, we explore the provocative idea that ketamine’s rapid antidepressant effect might be due to this temporary, total electromagnetic reset—a complete shaking of the “snow globe” that forces the brain’s rigid, unhealthy field patterns to resettle into a more flexible configuration. This is mind-bending physics that reframes mental health treatment as an exercise in tuning the brain’s frequency. Reference: Hunt, T. (2025). Electrodynamics of the Psychedelic Experience. Preprints.org. https://doi.org/10.20944/preprints202509.1813.v1 The post The Electrodynamics of Ketamine appeared first on Talking Ketamine Podcast.

When stroke strikes, the damage doesn’t stop once the blood flow is restored. This episode dives into the dark side of recovery: the Ischemia-Reperfusion (IR) Injury, a devastating “second wave” of damage that causes lasting neurological deficits. We explore a fascinating preclinical study on esketamine, the S-enantiomer of ketamine. Researchers hypothesized that this powerful NMDA receptor antagonist could stop IR injury, which is fueled by excessive excitotoxicity. We reveal how esketamine, when administered immediately after blood flow is restored, actively helps the brain fight back. The findings are compelling: esketamine significantly reduced markers of cell membrane damage (MDA) and, crucially, bolstered the brain’s own antioxidant defense system in the vulnerable hippocampal CA1 region. This dose-dependent effect points toward a new therapeutic window, allowing intervention hours or even days after a clot is removed. Could ketamine be the neuroprotectant that finally helps save the tissue we just rescued? Tune in to understand the science behind this potential breakthrough and the challenge of finding the neuroprotective ‘sweet spot’ dose. Reference: Erfani, S., Amirhaidari, B., & Khoshnazar, S. M. (2025). Antioxidant Therapeutic Potential of S-Ketamin Against Cerebral Ischemia/Reperfusion Injury in Male Rats. Journal of Isfahan Medical School, 43(821), 749–758. https://doi.org/10.48305/jims.v43.i821.0749 The post Ketamine and Stroke Recovery appeared first on Talking Ketamine Podcast.

When traditional antidepressants fail older adults with treatment-resistant depression, where can they turn? Standard therapies, built on the monoamine hypothesis, often fall short in aging brains or those affected by neurodegenerative diseases like Alzheimer’s, as the pathways they rely on may be dysfunctional. This episode dives deep into a systematic review exploring a paradigm-shifting alternative: ketamine and its derivatives, esketamine and arketamine. These compounds sidestep conventional mechanisms, instead targeting the NMDA receptor to promote widespread neuroplasticity. We uncover the powerful clinical findings, revealing that ketamine provides rapid, robust relief and is equally effective in geriatric and non-geriatric populations. Discover how ketamine not only improves mood but also restores vital executive functions, helping patients think more clearly. We’ll explore the neurological data showing how the treatment restores the brain’s crucial “excitation-inhibition” balance, leading to more organized cognitive processing. While the immediate benefits are profound, we also confront the critical unresolved question of long-term sustainability. Join us to understand how this research challenges us to move beyond targeting single chemicals and toward therapies that aim to rebuild the entire circuitry of the mind. Reference Altamura, M., Leccisotti, I., Moretti, M. C., Bellomo, A., Panza, F., Cassano, T., & Lozupone, M. (2025). Can ketamine therapy overcome treatment-resistant depression in Alzheimer’s disease and older adults? Preclinical and clinical evidence. Biomedicine & Pharmacotherapy, 188, 118199. https://doi.org/10.1016/j.biopha.2025.118199 The post Ketamine and the Aging Brain appeared first on Talking Ketamine Podcast.

Ketamine is known for its powerful effects on the mind and body, but could one of its most profound secrets be the ability to fight cancer? In this episode, we explore groundbreaking new research that reveals an unexpected link between ketamine and cervical cancer cells. Discover the fascinating mechanism at play: ketamine appears to target the “power plants” (mitochondria) inside cancer cells, forcing them to shatter in a process called fission. This triggers a massive energy crisis, effectively stopping the cells in their tracks and pushing them toward self-destruction. We break down the specific molecular “switch” that researchers believe controls this process, offering a new level of precision in understanding how the drug works. But how does this lab research translate to the real world? We also discuss the critical questions around dosage and the long road from the petri dish to potential patient treatments. Join us for a clear and compelling look at the cutting edge of oncology, where a familiar drug may hold a surprising new key to exploiting one of cancer’s fundamental vulnerabilities. Reference Fang, L., et al. (2025). Ketamine induces apoptosis in cervical cancer cells by triggering mitochondrial fission via the RHOA/DRP1 pathway. Journal of Experimental & Clinical Cancer Research, 44(1), 112. https://doi.org/10.1002/jbt.70500 The post Ketamine vs Cervical Cancer appeared first on Talking Ketamine Podcast.

Why does ketamine provide miraculous relief for some people with severe depression but leave others behind? This episode unpacks a groundbreaking study that points to a surprising answer: hidden inflammation. Join us as we explore a pioneering 2025 paper that uses a novel method called Intron Retention (IR) to re-examine the biology of ketamine treatment. Researchers discovered that, even before treatment, those who don’t respond to ketamine often show signs of a highly active immune system, as if their body is fighting a persistent viral infection. Here’s the stunning twist: the study reveals that ketamine has a powerful anti-inflammatory effect in everyone—even in so-called “non-responders.” This challenges everything we thought we knew about treatment resistance. It suggests that for these individuals, ketamine isn’t ineffective, but rather insufficient to overcome the massive underlying inflammatory burden. This paradigm shift reframes “non-response” not as a failure, but as a signpost pointing toward a future of personalized medicine. Could combining ketamine with targeted anti-inflammatory or antiviral therapies unlock its potential for millions more? Listen now to understand the science that could revolutionize mental health care. Study Referenced: Okada, N., Oshima, K., Maruko, A. et al. Intron retention: a novel method for evaluating the response to ketamine in patients with treatment-resistant depression. npj Mental Health Res 4, 44 (2025). https://doi.org/10.1038/s44184-025-00161-7 The post Ketamine vs Inflammation appeared first on Talking Ketamine Podcast.

Ketamine is known for its rapid antidepressant effects, but what if the experience itself could be made more profound and therapeutic? In this episode, we explore new research investigating whether a combination of mindfulness training, music, and an eye mask could enhance the ketamine journey for individuals with clinical depression. While the study found that adding these sensory elements did not significantly change ketamine’s effect on depression scores, it did profoundly enrich the subjective experience for participants. Listen to learn how the combined intervention group reported: Greater engagement with the experience A stronger connection to reality, even in an altered state An increased ability to tame negative thoughts A more profound sense of awe, including feelings of self-diminishment and vastness, which were rarely reported in the control group The episode also discusses the study’s nuances and limitations, including an increased frequency of transient negative experiences like heightened anxiety and fear in the combined group. However, participants seemed to be better able to manage these feelings, suggesting a more “navigable” experience. This episode is for anyone interested in maximizing ketamine’s therapeutic potential. It highlights how intentionally designed environments can make a healing process more integrated and meaningful, even with simple, low-burden additions. Study Citation Kirka, J., McDonald, C., Walter, C., Price, P., & Zara, Z. (2025). Mindfulness Music and Visual Occlusion in Ketamine: A Mixed Method study on Subjective experience and Antidepressant effects. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1642025 The post Deepening the Ketamine Experience appeared first on Talking Ketamine Podcast.

Can a drug known for pain and mental health treatments also be a weapon against cancer? In this episode of Talking Ketamine, hosts Helios and Selene delve into a surprising new area of research: ketamine and its potential role in fighting cancer.The episode explores a 2024 study on “perioperative ketamine and cancer recurrence” and the complex science behind it. You’ll learn how ketamine’s well-known anti-inflammatory effects could be crucial, as chronic inflammation is a key factor in tumor growth and metastasis. Helios and Selene discuss compelling evidence, including a randomized trial of over 100 colorectal surgery patients, where a single, low dose of ketamine significantly reduced inflammatory markers. They also touch on how the drug may work at a molecular level by inhibiting transcription factors that turn on inflammatory genes.However, the conversation doesn’t shy away from the complexities and contradictions. You’ll hear about a mouse study where ketamine was linked to a reduction in metastases, but also about other research that warns it could potentially suppress immune cells vital for fighting cancer. The hosts also address concerns that ketamine might help cancer cells survive by boosting a protein called BCL2.This is a double-edged sword, and the episode emphasizes that the context—dose, timing, and type of cancer—is everything. They underscore that more research is needed to understand the long-term clinical implications for patients. If you have a background in science, you’ll appreciate their clear breakdown of the immune system’s intricate relationship with ketamine and the idea that a personalized approach might be the future of this research.Reference:Rodriguez Arango, J. A., Zec, T., & Khalife, M. (2024). Perioperative Ketamine and Cancer Recurrence: A Comprehensive Review. Journal of Clinical Medicine, 13(7), Article 1920. https://doi.org/10.3390/jcm13071920The post Ketamine vs Cancer appeared first on Talking Ketamine Podcast.

Dive into the profound and complex world of ketamine therapy in this episode of the Talking Ketamine podcast, where we explore “The Paradox of Hope”. We unpack a powerful qualitative study, “Lived Futures in Ketamine Therapy: A Qualitative Study of Hope and Temporality in Treatment Resistant Depression” , which gives us a raw, unfiltered look into the lives of individuals battling severe treatment-resistant depression. Discover the deep-seated hopelessness that years of failed treatments can create. You’ll hear about the “therapeutic burden” that chips away at a person’s spirit, leaving them with an “active, almost protective disbelief” in the possibility of recovery. Then, witness the shocking “temporal rupture” that ketamine’s rapid effects create, forcing patients to reconcile a lifetime of futility with immediate, undeniable change. This episode explores how patients navigate the societal stigma of a drug often labeled a “party drug” and how the clinical setting provides a crucial sense of legitimacy and safety. Most importantly, we reveal how ketamine fosters a new, more resilient form of hope—one that is “grounded in real results” and tangible changes. This transformation allows patients to separate their identity from their illness , viewing it as a “brain problem” that can be fixed, rather than a personal failing. Join us as we explore how a medical innovation can fundamentally reshape what it means to heal, offering a truly “tangible, evidence-based possibility for everyone who needs it”. APA Citation of Subject Study:Ninnemann, K. M. (2025). Lived futures in ketamine therapy: A qualitative study of hope and temporality in treatment-resistant depression [Doctoral dissertation, Case Western Reserve University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=case1749123703760677 The post Ketamine and the Paradox of Hope appeared first on Talking Ketamine Podcast.

Ketamine can lift the fog of severe depression in hours, but what happens when that relief fades just as quickly? This has been the biggest hurdle in using it as a long-term solution for those battling the most persistent and treatment-resistant forms of depression. This episode examines a brand-new 2025 study that explores the groundbreaking strategy of maintenance ketamine infusions. We unpack compelling real-world evidence from a community clinic, looking at how regular, spaced-out IV treatments could be the key to sustained wellness. The findings are significant: researchers saw lasting improvements in patients with both treatment-resistant major depressive disorder (TRD) and—for the first time in a maintenance study—bipolar depression (TRBD). Join us as we reveal the data on how long these benefits can last, extending the period of wellness from just one or two weeks to a median of six weeks and an average of 10-12 weeks. We also explore the critical findings on the sustained reduction in suicidal thoughts, offering a powerful beacon of hope. Finally, we provide a balanced look at the safety of long-term infusions and the unique insights and limitations of this type of real-world research. Is this the key to transforming ketamine from a temporary rescue into an enduring management tool?  Listen now to explore the future of chronic depression care. Based on this paper: Haikazian, S., McIntyre, R. S., Meshkat, S., Kratiuk, K., Llach, C.-D., Orsini, D. K., Di Luch, S. D., & Rosenblat, J. D. (2025). Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder. Psychiatry Research, 352, 116691. https://doi.org/10.1016/j.psychres.2025.116691

In this episode, we tackle the complex challenge of co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). Traditional treatments often fall short, leaving many seeking new hope. This episode unpacks a groundbreaking study by Yoon, Crystal, and colleagues from VA Connecticut and Yale. They explored ketamine’s efficacy in a rigorous, three-arm, double-blind trial with 65 adults struggling with both MDD and AUD. While initial depression relief was seen across all groups, ketamine’s antidepressant effects proved significantly more durable. Surprisingly, naltrexone, an opioid blocker, didn’t diminish ketamine’s mood benefits, challenging existing theories about its mechanism. This points to other pathways, like the glutamate system, as crucial. Though ketamine didn’t directly reduce alcohol use or craving more than the control , it showed remarkable improvements in anxiety and overall quality of life. Fascinatingly, adding naltrexone to ketamine led to even greater anxiety reduction, suggesting a targeted benefit for this combination. Join us as we reveal these nuanced findings, offering considerable hope for those battling both MDD and AUD. Discover how ketamine’s lasting impact on mood, anxiety, and well-being could reshape personalized treatment approaches. Reference: Yoon, G., Pittman, B., Ralevski, E., Petrakis, I. L., & Krystal, J. H. (2025). Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: A randomized controlled trial. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf056 The post Ketamine vs Alcohol Use Disorder appeared first on Talking Ketamine Podcast.

Welcome to Talking Ketamine, Episode 26, where we’re delving into a fascinating and often overlooked aspect of psychedelic research: the very tone of scientific conversation itself! You know that ketamine and psilocybin are generating immense buzz for their therapeutic potential, especially for tough conditions like treatment-resistant depression. But is the academic literature a unified voice of optimism? Not at all. It’s a complex tapestry woven with threads of cautious optimism and critical concern about abuse and risk. In this episode, we unpack groundbreaking research from a Master’s thesis by Oksana Abramova, which employs cutting-edge AI to map these intricate narrative shifts. Using a fine-tuned SciBERT language model, specially trained on scientific texts, the AI meticulously predicts sentiment – the positive or negative leaning – even within the subtle, hedged language (think “suggests” instead of “proves”) characteristic of academic writing. Complementing this, BERTopic identifies the dominant themes, revealing whether the focus is on therapeutic benefits or potential harms. The findings are truly insightful. You’ll discover how psilocybin research shows a clear trend of increasing positivity in recent years, mirroring its re-emergence as a therapeutic tool. But ketamine’s scientific narrative reveals a more stable sentiment trajectory. Why the difference? We explore how ketamine’s longer, more controversial history – as an anesthetic and a substance with abuse potential – likely contributes to this consistent, balanced tone. Beyond overall trends, we reveal how sentiment can shift dramatically even within a single research paper, from hopeful abstracts to cautious discussion sections that thoroughly explore limitations. Perhaps most surprisingly, the AI analysis discovers a weak correlation between a paper’s topic and its sentiment. This means an article focused on therapeutic use isn’t necessarily overflowing with positivity; it might instead reflect a rigorous, critical examination of treatment claims. Conversely, a paper detailing risks could still carry an underlying hopeful tone, emphasizing the importance of understanding dangers to enable safe therapeutic application. This episode offers a unique lens, showing how AI helps us to look deeper than the headlines, appreciating the full, nuanced spectrum of scientific discourse. It’s a powerful reminder that truly understanding research means grasping not just what is said, but how it’s said, revealing the evolving perspectives and inherent caution of good science. Don’t miss this opportunity to understand the hidden dynamics shaping the future of psychedelic medicine. Reference: ABRAMOVA, O. (2024). Analysing Valence Shifts in Scientific Narratives on Psychedelics using BERT and Topic Modeling. https://thesis.unipd.it/handle/20.500.12608/89824 The post Ketamine Research Sentiment appeared first on Talking Ketamine Podcast.

Imagine a future where the grip of traumatic experiences could truly be lessened, not just managed. In this episode, we explore groundbreaking research on how ketamine might influence our fear memories, offering a profound potential for PTSD treatment and trauma recovery. Post-traumatic stress disorder (PTSD) is a debilitating condition marked by intrusive memories, flashbacks, and constant hypervigilance after traumatic events. Standard treatments like psychotherapy (e.g., prolonged exposure) and medication often fall short, with high dropout and low response rates, highlighting a desperate need for better options. Our discussion centers on “fear memory extinction” – a crucial learning process where the brain learns that a previously threatening stimulus is now safe. It’s not about forgetting trauma, but about overriding old fear associations with new safety learning. How does ketamine fit in? At lower, subanesthetic doses, ketamine appears to work by inhibiting specific brain “brakes,” leading to a paradoxical surge in glutamate – the brain’s main excitatory chemical. This cascade then boosts BDNF (“brain fertilizer”) and promotes synaptic plasticity, essentially making the brain more receptive to forming new, healthier connections. It’s like ketamine opens a “window for enhanced plasticity and learning,” ready for rewiring. A recent comprehensive preclinical review (Boese et al., 2025) synthesized 15 studies on ketamine’s impact on fear memory extinction in animals. The findings are compelling: two-thirds of studies showed ketamine significantly enhanced fear extinction, helping animals reduce fear responses more effectively. However, the picture isn’t entirely uniform. Some studies reported impairment, particularly linked to intravenous (IV) infusion and a subsequent surge in stress hormones like noradrenaline, which could inadvertently strengthen fear memories. This highlights the critical importance of dosage, administration route, and timing. Timing is especially crucial. Research suggests that if fear extinction training (like prolonged exposure therapy) occurs when traumatic memories are in a temporary “malleable” state – a process called reconsolidation – it could effectively “rewrite” the memory to be less fearful and more resistant to relapse. Ketamine might play a pivotal role in opening or extending this window of opportunity. Furthermore, initial evidence suggests potential sex differences in how ketamine is processed and its effects, underscoring the need for personalized approaches. This preclinical promise is already translating to human trials. A major double-blind, randomized controlled trial is currently underway with 100 veterans suffering from PTSD, exploring IV ketamine as an adjunct to prolonged exposure therapy. The ketamine or placebo is administered one day prior to therapy sessions, aiming to “prime” the brain for more effective safety learning. The core message is profound: ketamine has the clear potential to enhance the brain’s own natural ability to unlearn fear. It’s not just about temporary symptom relief, but about facilitating a deeper, more fundamental shift in how the brain processes traumatic memories, enabling a more lasting change and helping individuals reclaim their sense of safety and well-being. Reference: Boese, M., Berman, R., Radford, K., Johnson, L. R., & Choi, K. (2025). Effects of ketamine on fear memory extinction: a review of preclinical literature. Frontiers in Neuroscience, 19, 1546460. https://doi.org/10.3389/fnins.2025.1546460 The post Ketamine vs Fear Memories appeared first on Talking Ketamine Podcast.

Dive into Ketamine’s incredible versatility! This episode explores how tailoring ketamine dosing strategies is key to unlocking its potential across a surprisingly wide range of conditions, from severe depression to pain management. Learn why it’s considered a “reset button” for disrupted brain pathways due to its unique action on NMDA receptors, leading to rapid anti-depressant effects often within hours. The episode highlights the crucial need for individualized treatment plans, emphasizing that the optimal dose and delivery method — whether intravenous, intramuscular, or subcutaneous — vary greatly depending on the patient’s age, weight, other medical conditions, and even co-occurring medications. Discover why it’s not simply a case of “more is better,” with moderate, subanesthetic doses often proving most effective for depression in an “inverted U-shaped” dose-response curve. Understand how repeated infusions can lead to longer-lasting benefits beyond a single dose, making it a promising option for sustained relief in treatment-resistant cases. This deep dive underscores that ketamine is a powerful tool that requires expert handling and careful monitoring to balance its remarkable therapeutic potential with potential risks and side effects. Based on the 2025 review: Optimizing Ketamine Dosing Strategies across Diverse Clinical Applications: A Comprehensive review. [http://dx.doi.org/10.1097/MS9.0000000000003580] The post Ketamine Dosing Strategies appeared first on Talking Ketamine Podcast.

We delve into how ketamine’s unique altered states of consciousness, like ego dissolution and dissociation, could serve as a blueprint for future brain-computer interfaces. This episode reveals how neurochemistry might inspire technology to design new modes of consciousness, going beyond simply repairing the brain to potentially enhancing or redesigning consciousness itself. Learn more from the study discussed: Wilson, J. A., Johnson, S. E., & Price, D. J. (2023). Neurochemical Horizons: Elon Musk, Ketamine, and the Future of Neural Interface Design. ResearchGate. https://doi.org/10.13140/RG.2.2.20903.05287 The post Ketamine & Neuroethics appeared first on Talking Ketamine Podcast.

Dive into a fascinating single case study that spotlights the potential of sublingual ketamine troches for those battling tough mental health challenges. Discover how one patient with treatment-resistant depression, PTSD, and social anxiety disorder found significant relief and was able to reduce multiple medications. This episode unpacks a compelling real-world story, offering insights into ketamine’s promise as a less invasive, accessible option for complex cases. Find the study discussed in this episode here: Wilson, J. A., Johnson, S. E., & Price, D. J. (2023). Symptom Reduction and Deprescribing in a Patient With Treatment-Resistant Depression Using Sublingual Ketamine Troches: A Case Report. Cureus, 15(4), e383995. https://doi.org/10.7759/cureus.383995 The post Sublingual Ketamine appeared first on Talking Ketamine Podcast.

Discover the fascinating world of Ketamine Assisted Therapy (KAT) and its promise for depression. We dive deep into “set and setting” – how your mindset and environment can profoundly transform the healing journey – all from the vital perspective of those who’ve experienced it. Explore what truly makes for the best possible KAT experience. Read the full study: Stockwell, G., Hoeh, N. R., Fogarty, F., Clayden, C., & Reynolds, L. (2025). Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context. Journal of Psychoactive Drugs. Advance online publication. https://doi.org/10.1080/02791072.2025.2527299 The post KAT Set & Setting appeared first on Talking Ketamine Podcast.

In this episode, we explore groundbreaking research on a formidable clinical challenge: co-occurring major depressive disorder (MDD) and opioid use disorder (OUD). A new randomized clinical trial compared adjunctive ketamine and buprenorphine, revealing significant reductions in both anxiety symptoms and craving intensity for patients with these co-occurring conditions. The study found that ketamine demonstrated a rapid reduction in anxiety and a pronounced decline in opioid craving within hours of administration. In contrast, buprenorphine was associated with a more gradual but sustained improvement in anxiety symptoms over several days, along with a modest initial reduction in opioid craving followed by persistent attenuation. Tune in to understand these distinct treatment trajectories and the promising implications for managing this challenging patient population. Read the full study here: Mansoori, F., Ramezanli, M., Asadi, P., & Mohammadi, A. (2025). Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity. Trials, 26(1), 133. https://doi.org/10.1186/s13063-025-08836-4 The post Ketamine for Opioid Addiction appeared first on Talking Ketamine Podcast.

This episode tackles the profound challenge of treatment-resistant depression (TRD), a severe mental illness affecting 280 million people globally. While low-dose subanesthetic intravenous ketamine treatment has shown rapid improvement for TRD, its effects are often transient, lasting only days to weeks, and IV administration can be impractical and expensive for long-term use. We shift focus to a novel, more accessible approach: very low-dose subcutaneous ketamine. Drawing on a unique case report, we explore its potential as a maintenance option for severe TRD. This method is highlighted for being less invasive, more cost-effective, practical, and accessible, potentially offering a more gradual absorption that could decrease adverse effects. The case study featured a patient with severe TRD who, after 15 years of struggle, achieved a stable mental state and maintained occupational functioning for four years with subcutaneous ketamine. Study discussed: Can, A. T., Hermens, D. F., & Lagopoulos, J. (2022). A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression. Clinical Case Reports, 10(12), e6675. https://doi.org/10.1002/ccr3.6675 The post Subcutaneous Ketamine appeared first on Talking Ketamine Podcast.

Explore a groundbreaking single case study from 2025 on ketamine-assisted psychotherapy (KAP) for the notoriously challenging anorexia nervosa (AN). Discover how KAP, coupled with Acceptance and Commitment Therapy (ACT), potentially creates a “neuroplastic window” for change in rigid thought patterns. The case study reveals marked symptom reduction in AN pathology, depression, and anxiety, alongside improved quality of life for one patient. This unique case highlights the critical synergy between ketamine and therapy for sustained gains, while also navigating complexities like post-treatment weight loss and a subsequent psilocybin experience. It’s a powerful glimpse of hope for treatment-resistant conditions, demanding further rigorous research. Find the full report here: De Smet, L., De Schryver, M., Roekens, L., Van Vlierberghe, L., Dierckx, M., Van Renterghem, K., Van Ryckeghem, D., & Kiekens, G. (2025). Transdiagnostic ketamine and psycholytic psychotherapy for patients with co-occurring depression and eating disorder: study protocol of a randomized controlled trial. Journal of Eating Disorders, 13(1), 108. https://doi.org/10.1186/s40337-025-01313-y The post Ketamine and Anorexia Nervosa appeared first on Talking Ketamine Podcast.

Dive into the incredible, 60-year saga of ketamine! Our deep dive explores the fascinating journey of this molecule, originally known as CI-581, from its origins as an ‘older sibling’ to PCP (phencyclidine). Discover how it became the subject of the first-in-human study for a novel anesthetic. Learn about its unique status as the only “dissociative anesthetic”, noted for rapid onset, short duration, and minimal adverse cardiovascular or respiratory effects, yet also for its distinct psychic “syndrome” that led to the term “dissociative anesthesia”. Explore how ketamine faced controversy and fell out of favor due to psychotomimetic effects and patient nightmares, only to experience a “rebirth” through scientific understanding of its NMDA receptor antagonism and the use of benzodiazepines to mitigate side effects. Witness its dramatic resurgence in anesthesiology and pain management, driven by the opioid crisis, making opioid-sparing anesthesia ubiquitous. Most recently, delve into its “explosive” life as a rapid-acting antidepressant, a discovery that has revolutionized psychiatry and led to the FDA approval of S(+)-ketamine nasal spray. Ketamine’s story highlights its pharmacologic complexity and its role as a “pharmacologic agent provocateur”, challenging classical drug development paradigms by showing effects that “outlast” plasma exposure. This powerful journey raises critical questions about modern drug discovery and whether such a complex molecule would even be approved today. Learn more in the insightful commentary that guided this episode: Kharasch, E. D. (2023). The Nine Lives of Ketamine from CI-581 to Present Day Clinical Application—Commentary on Domino et al. Clinical Pharmacology & Therapeutics. Advance online publication. https://doi.org/10.1002/cpt.3634 The post Ketamine’s 9 Lives appeared first on Talking Ketamine Podcast.

Uncover a crucial, rarely discussed topic on the potential effects of ketamine on sexual health. We delve into a 2023 systematic review by Pominville et al., which included four studies. These limited findings, primarily from studies of illicit, heavy, long-term ketamine use, suggest a potential correlation with sexual dysfunction. This episode critically highlights a significant research gap regarding medical ketamine use. Tune in to understand what the current, albeit limited, science indicates and why more research is urgently needed in clinical populations. Link to the systematic review discussed: Pominville, R., Loria, M., Fraiman, E., & Mishra, K. (2023). Sexual Dysfunction Related to Ketamine Use: a Systematic Review. Current Sexual Health Reports, 15(4), 125–131. https://doi.org/10.1007/s11930-023-00363-0   The post Ketamine and Sexual Health appeared first on Talking Ketamine Podcast.

Ketamine therapy is increasingly explored for mental health, but what about the potential risks? In this crucial episode, we delve into the landscape of ketamine use disorder, drawing on insights from a significant 2025 study based on the direct experiences of 274 individuals with KUD. Learn about the common physical warning signs reported by people with KUD, including prevalent bladder and nasal problems, and the intense ‘K-cramps’. Discover the challenging abstinence and withdrawal symptoms they experienced when trying to cut back or stop, such as intense cravings, low mood, and anxiety. The episode also highlights a striking finding: the significant lack of awareness among users, peers, and even professionals regarding ketamine’s risks and addictive potential. Whether you’re considering or currently undergoing ketamine therapy, this episode provides vital information on signs to look out for and underscores the importance of open conversations with healthcare providers to navigate this treatment both effectively and safely. Read the study discussed in this episode: Harding, R. E., Barton, T., Niepceron, M., Harris, E., Bennett, E., Gent, E., Fraser, F., & Morgan, C. J. A. (2025). The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. Addiction. Advance online publication. https://doi.org/10.1111/add.70073 The post Ketamine Use Disorder Warning Signs appeared first on Talking Ketamine Podcast.

This episode dives into the real experiences and personal stories of individuals who have undergone ketamine-assisted therapy (KAT), exploring how this approach might differ from using ketamine alone. The discussion is based on a phenomenological study that conducted in-depth interviews with 10 people six or more months after they completed ketamine assisted psychotherapy (PAT/KAT/PAP). Participants shared their motivations for seeking KAT, often after traditional therapies felt ineffective or insufficient for their deep-seated issues, sometimes complicated by physical health problems. The study sought the “real lived story” of what happens when ketamine is combined with therapy, what shifts occur, and if they are lasting. Key insights from their experiences during KAT sessions included profound emotional release and catharsis. Sessions were varied and deeply personal. A significant focus was working on core negative beliefs like “I’m not good enough” and finding self-acceptance, potentially aided by the altered state and the therapeutic relationship. Looking back months later, participants reported significant, lasting improvements in emotional regulation and coping with stress. They described healthier relationships with self and others, including setting boundaries, and engaged in self-care practices. These changes were consistently described as a “turning point,” “catalyst,” or “profound transformation”. These accounts offer a sense of hope and provide compelling insights about the value and impact of combining ketamine with dedicated therapy. Bricker, M. K. (2025). Understanding Change Following Psychedelic-Assisted Therapy: A Phenomenological Study. (Doctoral dissertation, Liberty University). https://digitalcommons.liberty.edu/cgi/viewcontent.cgi?article=7899&context=doctoral The post Ketamine Assisted Therapy appeared first on Talking Ketamine Podcast.

Step inside a ketamine therapy session for depression, from the patient’s point of view. In this episode of Talking Ketamine (episode 13), we look at the immediate personal experience, drawing on a qualitative study published in 2021. This study interviewed 13 people with treatment-resistant depression about what it was like during and right after their ketamine infusions. Participants described initial sensations during the infusion including a feeling like a high, enhanced perception (sounds and sights more intense, colors more vibrant), and dissociation, sometimes feeling detached or having an out-of-body experience. Many also felt very relaxed, even sleepy. In the hours and days following the infusion, many reported a significant uplifted feeling and a real brightened mood. They described feeling bright, using phrases like having “fire in their belly”, and contrasting it with depression, which felt like “lifting darkness away like a weight just gone”. Beyond mood, there was a noticeable boost in motivation and the ability to do everyday tasks they’d struggled with, like cooking or being sociable. Relationships could feel stronger. Cognitively, people had more positive thoughts and fewer negative ones. A very significant finding was a major reduction in suicidal ideation, moving towards wanting to live again and seeing a future. Some felt their mindset was reframed or reprogrammed, describing the change as going from “gray and black” to “technicolor”. The experience was also shaped by the conducive and safe environment and feeling supported by caring staff. Important Note: The study highlighted that not everyone responds the same way, some are non-responders, and the duration of positive effects varies greatly. However, these firsthand accounts offer powerful insights into the potential impact of ketamine for those with severe depression. Griffiths, C., Walker, K., Reid, I., Maravic da Silva, K., & O’Neill-Kerr, A. (2021). A qualitative study of patients’ experience of ketamine treatment for depression: The ‘Ketamine and me’ project. Journal of Affective Disorders Reports, 4, 100079. https://doi.org/10.1016/j.jadr.2021.100079 The post First Person Experiences appeared first on Talking Ketamine Podcast.